Biotech · Private company
Genfit
Track this companyFree. Adds Genfit to your Dealase workspace and tells you when its record changes.
Clinical trials111 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- ElafibranorPhase 3 · Nonalcoholic Steatohepatitis (NASH) With FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- Elafibranor 120 mgPhase 2 · Primary Biliary Cholangitis (PBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Elafibranor 120mgPhase 2 · Non Alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Elafibranor 80 mgPhase 2 · Primary Biliary Cholangitis (PBC)ClinicalTrials.gov · fetched Nov 12, 2026
- Elafibranor 80mgPhase 2 · Non Alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- GFT505 120mgPhase 2 · Non-Alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- GFT505 80mgPhase 2 · Non-Alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- GNS561 + TrametinibPhase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- SOCPhase 2 · Hepatic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- SOC (Control Group)Phase 2 · Acute-On-Chronic Liver FailureClinicalTrials.gov · fetched Nov 12, 2026
- VS-01 on top of SOCPhase 2 · Acute-On-Chronic Liver FailureClinicalTrials.gov · fetched Nov 12, 2026
- VS-01 on top of SOC (Active Treatment Group)Phase 2 · Hepatic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- ElafibranorPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Multiple dosing of G1090NPhase 1 · Acute-on-Chronic Liver FailureClinicalTrials.gov · fetched Nov 12, 2026
- NitazoxanidePhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- NitazoxanidePhase 1 · Moderate Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Single Dose G1090NPhase 1 · Acute-on-Chronic Liver FailureClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy VolunteersPHASE1 · COMPLETED · started Aug 26, 2025ClinicalTrials.gov NCT07110441 · fetched Nov 12, 2026
- A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic EncephalopathyPHASE2 · TERMINATED · started Aug 25, 2025ClinicalTrials.gov NCT06987968 · fetched Nov 12, 2026
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaPHASE1_PHASE2 · RECRUITING · started Aug 21, 2023ClinicalTrials.gov NCT05874414 · fetched Nov 12, 2026
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®PHASE2 · TERMINATED · started Jul 2, 2023ClinicalTrials.gov NCT05900050 · fetched Nov 12, 2026
- Nitazoxanide Pharmacokinetic Parameters in Renal Impaired SubjectsPHASE1 · COMPLETED · started Apr 25, 2022ClinicalTrials.gov NCT05368935 · fetched Nov 12, 2026
- Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired PatientsPHASE1 · COMPLETED · started Nov 5, 2021ClinicalTrials.gov NCT05116826 · fetched Nov 12, 2026
- Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)PHASE2 · TERMINATED · started Jun 25, 2019ClinicalTrials.gov NCT03883607 · fetched Nov 12, 2026
- Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsPHASE1 · COMPLETED · started Dec 12, 2018ClinicalTrials.gov NCT03765671 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic AcidPHASE2 · COMPLETED · started Apr 5, 2017ClinicalTrials.gov NCT03124108 · fetched Nov 12, 2026
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)PHASE3 · TERMINATED · started Mar 1, 2016ClinicalTrials.gov NCT02704403 · fetched Nov 12, 2026
- Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01694849 · fetched Nov 12, 2026